期刊
ACTA NEUROPATHOLOGICA COMMUNICATIONS
卷 8, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s40478-020-01004-6
关键词
alpha-Synuclein; beta-Hexosaminidase; Sandhoff disease; Parkinson's disease; Neuroprotection; Lipid binding
资金
- Michael J. Fox Foundation for Parkinson's Research award [15595]
- NIH/NINDS [1R01NS092667]
- NIH/NIA [R01AG060195]
- DoD [W81XWH2010368, W81XWH2010371]
- Consolidated Anti-Aging Foundation
- Orchard Foundation
- Harold and Ronna Cooper Post-Doctoral Fellowship for Parkinson's Disease Research
- Parkinson's UK
- Royal Society
- U.S. Department of Defense (DOD) [W81XWH2010371, W81XWH2010368] Funding Source: U.S. Department of Defense (DOD)
Sandhoff disease (SD) is a lysosomal storage disease, caused by loss of beta-hexosaminidase (HEX) activity resulting in the accumulation of ganglioside GM2. There are shared features between SD and Parkinson's disease (PD). alpha-synuclein (aSYN) inclusions, the diagnostic hallmark sign of PD, are frequently found in the brain in SD patients and HEX knockout mice, and HEX activity is reduced in the substantia nigra in PD. In this study, we biochemically demonstrate that HEX deficiency in mice causes formation of high-molecular weight (HMW) aSYN and ubiquitin in the brain. As expected from HEX enzymatic function requirements, overexpression in vivo of HEXA and B combined, but not either of the subunits expressed alone, increased HEX activity as evidenced by histochemical assays. Biochemically, such HEX gene expression resulted in increased conversion of GM2 to its breakdown product GM3. In a neurodegenerative model of overexpression of aSYN in rats, increasing HEX activity by AAV6 gene transfer in the substantia nigra reduced aSYN embedding in lipid compartments and rescued dopaminergic neurons from degeneration. Overall, these data are consistent with a paradigm shift where lipid abnormalities are central to or preceding protein changes typically associated with PD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据